Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 437, 1087 (20 October 2005) | doi:10.1038/4371087b; Published online 19 October 2005
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Assistant / Associate Professor
- Yale University
- New Haven, CT
Postdoctoral Position
- Fox Chase Cancer Center
- Philadelphia, Pennsylvania, United States, 19111
In brief
Brazil and Abbott Laboratories have averted a patent showdown by announcing that they have agreed on pricing for a key AIDS drug.Beginning next March, the Illinois-based drug company will make the protease inhibitor Kaletra (lopinavir and ritonavir) available to the Brazilian government for 63 US cents a pill, rather than the current price of $1.
To read this story in full you will need to login or make a payment (see right).
